Amgen
US biopharmaceutical company; participated in Quantinuum's $300M 2024 equity round as a strategic investor, alongside exploring quantum-computing applications for drug discovery.
Amgen is a major U.S. biopharmaceutical company headquartered in Thousand Oaks, California, founded in 1980. One of the world's largest independent biotech firms, it reported roughly $36.8B in 2025 revenue. Amgen's involvement in defense/deep-tech is limited to a single strategic corporate investment: it participated in Quantinuum's $300M equity round (closed January 2024, $5B pre-money valuation), alongside Honeywell, JPMorgan Chase, and Mitsui & Co. The relationship predates the funding round — Amgen has used Quantinuum's trapped-ion quantum computers for computational biology and molecular modeling research, and the investment formalized an existing R&D collaboration aimed at applying quantum computing to drug discovery.
Overview
- Firm
- Amgen Inc.
- Headquarters
- Thousand Oaks, CA
- Founded
- 1980
- AUM
- Stages
- Thesis
Partners0
No linked records yet.
Sources & citations2
Each claim links to its underlying source. Confidence reflects how directly the source supports the claim.
- 1
Honeywell announces closing of $300M equity round for Quantinuum at $5B pre-money valuation, naming Amgen as a participant
Honeywell: Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money ValuationVerified2024-01-16 - 2
Corroborating coverage naming Amgen, JPMorgan, Mitsui, Honeywell as Quantinuum's $300M round participants
Fierce Electronics: Quantinuum Gets $300M From JPMorgan, Amgen, Mitsui, HoneywellVerified2024-01-16